NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
India Glycols Schedules NCLT-Convened Creditors Meeting for Demerger on March 24, 2026
India Glycols Limited (IGL) is progressing with its corporate restructuring plan to demerge businesses into Ennature Biopharma Limited and IGL Spirits Limited. Following orders from the NCLT Allahabad Bench, the company has scheduled a meeting of its unsecured creditors on March 24, 2026, to seek approval for the Scheme of Arrangement. This follows similar procedural steps for shareholders and is a mandatory regulatory requirement for the demerger to proceed. The remote e-voting for eligible creditors is set to take place between March 20 and March 23, 2026.
முக்கிய அம்சங்கள்
NCLT-convened meeting of unsecured creditors scheduled for March 24, 2026, via Video Conferencing.Scheme involves the demerger of units into two resulting companies: Ennature Biopharma Limited and IGL Spirits Limited.Remote e-voting period is set from March 20, 2026 (9:00 AM) to March 23, 2026 (5:00 PM).The cut-off date for determining the eligibility of unsecured creditors to vote was November 15, 2025.
👀 கவனிக்க வேண்டியவை
Investors should track the outcome of these meetings as the demerger will lead to the creation of specialized entities for biopharma and spirits. No immediate action is required, but the restructuring is a key milestone for potential value unlocking.
India Glycols Reschedules NCLT-Directed Shareholder Meeting to March 24, 2026
India Glycols Limited has received a revised order from the NCLT Allahabad Bench regarding its proposed Scheme of Arrangement involving Ennature Biopharma and IGL Spirits. The meetings for equity shareholders and unsecured creditors, originally set for March 9, 2026, have been rescheduled to March 24, 2026. This administrative change was necessitated by the unavailability of the NCLT-appointed Chairperson on the original date. The meetings will be conducted via video conferencing to consider and approve the restructuring scheme.
முக்கிய அம்சங்கள்
NCLT Allahabad Bench approved rescheduling of shareholder and creditor meetings to March 24, 2026.The original meeting date was March 9, 2026, but was changed due to the Chairperson's unavailability.The Scheme of Arrangement involves India Glycols, Ennature Biopharma Limited, and IGL Spirits Limited.Meetings will be held via video conferencing under Sections 230 to 232 of the Companies Act, 2013.The rest of the NCLT order dated January 15, 2026, remains unchanged and valid.
👀 கவனிக்க வேண்டியவை
Investors should mark the new date of March 24, 2026, to participate in the voting process for the proposed demerger and arrangement. This is a routine administrative delay and does not reflect on the merits of the underlying transaction.
India Glycols Q3 FY26: Record EBITDA Growth of 36% and INR 582 Crore Debt Reduction
India Glycols Limited (IGL) reported record financial results for Q3 and 9M FY26, with 9M net revenue growing 11.4% to INR 3,235 crores. The company achieved a significant 28.9% increase in 9M EBITDA to INR 487 crores, with margins expanding to 15.0%. A major highlight was the reduction of debt by INR 582 crores during the quarter, funded by a INR 467 crore preferential allotment and internal accruals. Management remains optimistic about growth driven by premiumization in the Potable Spirits segment and high-margin Bio-based Specialty Chemicals.
முக்கிய அம்சங்கள்
9M FY26 Net Revenue increased by 11.4% YoY to INR 3,235 crores, while Q3 revenue rose 13%.EBITDA for 9M FY26 grew 28.9% to INR 487 crores, with Q3 EBITDA surging 36.1% YoY.Total debt was reduced by INR 582 crores in Q3, significantly lowering interest obligations.Potable Spirits segment revenue grew 17% YoY to INR 1,025 crores for the 9-month period.9M PAT stood at INR 206 crores, representing a 23% growth compared to the previous year.
👀 கவனிக்க வேண்டியவை
Investors should view the aggressive deleveraging and consistent margin expansion as strong indicators of improving financial health. The strategic shift toward premium spirits and specialty chemicals suggests a sustainable improvement in the quality of earnings.
India Glycols Q3FY26 Net Profit Rises 19% to ₹68 Cr; EBITDA Margins Expand to 16%
India Glycols reported a strong Q3FY26 with net revenue growing 13% YoY to ₹1,102 crore and EBITDA surging 36% to ₹176 crore. The company achieved a significant debt reduction of ₹582 crore, primarily through a preferential allotment, which is expected to lower interest costs significantly from Q4 onwards. Segmental performance was robust, particularly in Bio-Fuels where revenue jumped 45% and Bio-Based Specialties where EBIT margins expanded to 12.8%. The Potable Spirits division continues its premiumization strategy through the Amrut partnership and expansion into new markets like Kerala and CSD.
முக்கிய அம்சங்கள்
Consolidated Net Revenue for Q3FY26 grew 13% YoY to ₹1,102 Cr, while 9M PAT rose 23.4% to ₹206 Cr.EBITDA margins expanded by 277 bps YoY to 16.0% in Q3, driven by operational efficiencies and high-margin product focus.Total debt reduced by ₹582 Cr (₹467 Cr via preferential allotment), which will significantly reduce finance costs in future quarters.Bio-Fuel segment revenue surged 45.2% YoY to ₹394 Cr in Q3, supported by India's 20% ethanol blending target.Potable Spirits segment achieved 9M revenue of ₹1,025 Cr with a healthy EBIT margin of 21.2%.
👀 கவனிக்க வேண்டியவை
Investors should note the substantial debt reduction and margin expansion as key drivers for future profitability. The company's strategic shift toward premium spirits and high-margin specialty chemicals makes it a strong candidate for long-term growth.
India Glycols Q3 PAT Jumps 49% YoY to ₹65.26 Cr; Bio-Fuel Segment Revenue Grows 45%
India Glycols Limited (IGL) reported a robust performance for Q3 FY26, with standalone Net Profit rising 48.8% YoY to ₹65.26 crore. Revenue from operations increased 5.25% YoY to ₹2,551.06 crore, significantly supported by a 45% surge in the Bio-Fuel segment revenue. The company is actively pursuing a demerger of its Bio Pharma and Spirits & Biofuel undertakings into separate listed entities, with an appointed date of April 1, 2026. Furthermore, IGL strengthened its capital base by raising approximately ₹467 crore through a preferential allotment at ₹915 per share during the quarter.
முக்கிய அம்சங்கள்
Standalone Net Profit (PAT) grew 48.8% YoY to ₹65.26 crore vs ₹43.84 crore in the previous year.Bio-Fuel segment revenue surged 45% YoY to ₹394.28 crore from ₹271.54 crore.Profit Before Tax (PBT) increased 51% YoY to ₹88.30 crore despite a ₹0.83 crore exceptional charge related to new labour codes.Completed a preferential allotment of 51.03 lakh shares at ₹915 per share, raising ₹466.99 crore.The demerger process is on track with the NCLT Allahabad Bench allowing the first motion application on January 15, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming demerger as a major value-unlocking event and track the continued high growth in the Bio-Fuel segment. The recent fundraise at ₹915 per share indicates strong institutional confidence and provides a valuation benchmark for the current market price.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
India Glycols Receives NCLT Approval for First Motion of Three-Way Demerger Scheme
India Glycols Limited has received NCLT approval for the first motion of its scheme to demerge its 'Bio Pharma' and 'Spirits and Biofuel' undertakings into two separate entities, Ennature Biopharma and IGL Spirits. The NCLT has ordered meetings for equity shareholders and unsecured creditors while dispensing with meetings for secured creditors who provided 95.46% consent. Both resulting companies are intended to be listed on the NSE and BSE, aiming to unlock value and provide management focus for each distinct business segment. The appointed date for this restructuring is set for April 1, 2026.
முக்கிய அம்சங்கள்
NCLT Allahabad Bench allowed the first motion for demerging Bio Pharma and Spirits & Biofuel units.Secured creditors' meeting dispensed with after obtaining 95.46% consent in value.Resulting entities, Ennature Biopharma and IGL Spirits, are planned to be listed on NSE and BSE.The appointed date for the proposed Scheme of Arrangement is set as April 1, 2026.Equity shareholders of resulting companies provided 99.94% consent, leading to meeting dispensation.
👀 கவனிக்க வேண்டியவை
Investors should maintain a positive outlook as the demerger is likely to unlock value by creating specialized, listed entities for the biopharma and spirits businesses. Monitor the upcoming shareholder and creditor meetings for the final approval stages.
India Glycols: CGST Appeal Allowed, ₹1,92,12,510 Demand Dropped
India Glycols Limited received a favorable order from the Commissioner, CGST (Appeals), Noida, setting aside the earlier demand order issued by the Joint Commissioner, CGST, Noida. The original order had disallowed Transitional Input Tax Credit (ITC) and demanded ₹1,92,12,510 along with equivalent penalty and applicable interest. With the appeal being allowed, the demand for tax, penalty, and interest now stands dropped, resulting in no financial impact on the company.
முக்கிய அம்சங்கள்
Demand of ₹1,92,12,510 for disallowed Transitional Input Tax Credit (ITC) dropped.Order dated 28th January 2025 passed by Joint Commissioner, CGST, Noida, was set aside.Appeal allowed by Commissioner, CGST (Appeals), Noida on 26th November 2025.Order received by the company on 4th December, 2025.
👀 கவனிக்க வேண்டியவை
This is a positive development as it removes a contingent liability of ₹1,92,12,510. Investors can view this as a reduction in potential financial risk for India Glycols.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
